{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:39:37Z","timestamp":1772026777707,"version":"3.50.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The human monkeypox virus (Mpox) is classified as a member of the Poxviridae family and belongs to the Orthopoxvirus genus. Mpox possesses double-stranded DNA, and there are two known genetic clades: those originating in West Africa and the Congo Basin, commonly known as Central African clades. Mpox may be treated with either the vaccinia vaccination or the therapeutics. Modifying the smallpox vaccine for treating and preventing Mpox has shown to be beneficial because of the strong link between smallpox and Mpox viruses and their categorization in the same family. Cross-protection against Mpox is effective with two Food and Drug Administration (FDA)-approved smallpox vaccines (ACAM2000 and JYNNEOSTM). However, ACAM2000 has the potential for significant adverse effects, such as cardiac issues, whereas JYNNEOS has a lower risk profile. Moreover, Mpox has managed to resurface, although with modified characteristics, due to the discontinuation and cessation of the smallpox vaccine for 40 years. The safety and efficacy of the two leading mRNA vaccines against SARS-CoV-2 and its many variants have been shown in clinical trials and subsequent data analysis. This first mRNA treatment model involves injecting patients with messenger RNA to produce target proteins and elicit an immunological response. High potency, the possibility of safe administration, low-cost manufacture, and quick development is just a few of the benefits of RNA-based vaccines that pave the way for a viable alternative to conventional vaccines. When protecting against Mpox infection, mRNA vaccines are pretty efficient and may one day replace the present whole-virus vaccines. Therefore, the purpose of this article is to provide a synopsis of the ongoing research, development, and testing of an mRNA vaccine against Mpox.<\/jats:p>","DOI":"10.1186\/s12951-024-02355-1","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T17:02:34Z","timestamp":1709312554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["RETRACTED ARTICLE: An overview on mRNA-based vaccines to prevent monkeypox infection"],"prefix":"10.1186","volume":"22","author":[{"given":"Mohammad","family":"Natami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirsasan","family":"Gorgzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan","family":"Gholipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedeh Narges","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Firouzeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Zokaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Hasan","family":"Mohammed Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadis","family":"Kheradjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Sedighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaylan","family":"Kalavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"22","key":"2355_CR1","doi-asserted-by":"publisher","first-page":"2200421","DOI":"10.2807\/1560-7917.ES.2022.27.22.2200421","volume":"27","author":"A Antinori","year":"2022","unstructured":"Antinori A, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Eurosurveillance. 2022;27(22):2200421.","journal-title":"Eurosurveillance"},{"issue":"2","key":"2355_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1699-0463.1959.tb00328.x","volume":"46","author":"Pv Magnus","year":"1959","unstructured":"Magnus Pv, et al. A pox-like disease in cynomolgus monkeys. Acta Pathologica Microbiol Scand. 1959;46(2):156\u201376.","journal-title":"Acta Pathologica Microbiol Scand"},{"issue":"5","key":"2355_CR3","first-page":"599","volume":"46","author":"SS Marennikova","year":"1972","unstructured":"Marennikova SS, et al. Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ. 1972;46(5):599\u2013611.","journal-title":"Bull World Health Organ"},{"key":"2355_CR4","doi-asserted-by":"crossref","unstructured":"Sepehrinezhad A, Ashayeri Ahmadabad R, Sahab-Negah S. Monkeypox virus from neurological complications to neuroinvasive properties: current status and future perspectives. J Neurol, 2022.","DOI":"10.1007\/s00415-022-11339-w"},{"key":"2355_CR5","doi-asserted-by":"crossref","unstructured":"Forni D, et al. Geographic structuring and divergence time frame of monkeypox virus in the endemic region. The Journal of infectious diseases; 2022.","DOI":"10.1093\/infdis\/jiac298"},{"key":"2355_CR6","unstructured":"Yang Q et al. Highly accurate protein structure prediction and drug screen of monkeypox virus proteome. J Infect, 2022."},{"key":"2355_CR7","doi-asserted-by":"publisher","first-page":"102855","DOI":"10.1016\/j.jaut.2022.102855","volume":"131","author":"N Kumar","year":"2022","unstructured":"Kumar N, et al. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855.","journal-title":"J Autoimmun"},{"key":"2355_CR8","doi-asserted-by":"crossref","unstructured":"I\u00f1igo Mart\u00ednez J et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill, 2022. 27(27).","DOI":"10.2807\/1560-7917.ES.2022.27.27.2200471"},{"issue":"4","key":"2355_CR9","doi-asserted-by":"publisher","first-page":"e28701","DOI":"10.1002\/jmv.28701","volume":"95","author":"D Aden","year":"2023","unstructured":"Aden D, et al. Monkeypox (Mpox) outbreak during COVID-19 pandemic\u2014past and the future. J Med Virol. 2023;95(4):e28701.","journal-title":"J Med Virol"},{"issue":"1","key":"2355_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/14760584.2023.2198600","volume":"22","author":"BE Katamesh","year":"2023","unstructured":"Katamesh BE, et al. Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks? Expert Rev Vaccines. 2023;22(1):366\u20138.","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"2355_CR11","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1111\/1462-2920.16174","volume":"24","author":"J Chadha","year":"2022","unstructured":"Chadha J, et al. Insights into the monkeypox virus: making of another pandemic within the pandemic? Environ Microbiol. 2022;24(10):4547\u201360.","journal-title":"Environ Microbiol"},{"key":"2355_CR12","doi-asserted-by":"crossref","unstructured":"McCarthy MW. Therapeutic strategies to address monkeypox. Expert Review of Anti-infective Therapy, 2022(just-accepted).","DOI":"10.1080\/14787210.2022.2113058"},{"key":"2355_CR13","doi-asserted-by":"publisher","first-page":"104396","DOI":"10.1016\/j.amsu.2022.104396","volume":"81","author":"N Shaheen","year":"2022","unstructured":"Shaheen N, et al. Is there a need to be worried about the new monkeypox virus outbreak? A brief review on the monkeypox outbreak. Annals Med Surg. 2022;81:104396.","journal-title":"Annals Med Surg"},{"issue":"11","key":"2355_CR14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/14787210.2022.2128763","volume":"20","author":"S Nadar","year":"2022","unstructured":"Nadar S, Khan T, Omri A. Reemergence of monkeypox: prevention and management. Expert Rev Anti-infective Therapy. 2022;20(11):1425\u201333.","journal-title":"Expert Rev Anti-infective Therapy"},{"key":"2355_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijid.2022.06.047","volume":"122","author":"E Petersen","year":"2022","unstructured":"Petersen E, et al. Vaccination for monkeypox prevention in persons with high-risk sexual behaviours to control on-going outbreak of monkeypox virus clade 3. Int J Infect Dis. 2022;122:569\u201371.","journal-title":"Int J Infect Dis"},{"issue":"1\u20132","key":"2355_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","volume":"57","author":"RO Baker","year":"2003","unstructured":"Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003;57(1\u20132):13\u201323.","journal-title":"Antiviral Res"},{"issue":"3","key":"2355_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jcv.2006.03.012","volume":"36","author":"Y Li","year":"2006","unstructured":"Li Y, et al. Detection of monkeypox virus with real-time PCR assays. J Clin Virol. 2006;36(3):194\u2013203.","journal-title":"J Clin Virol"},{"issue":"7","key":"2355_CR18","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1021\/acs.jmedchem.3c00069","volume":"66","author":"J Wang","year":"2023","unstructured":"Wang J, et al. An overview of antivirals against monkeypox virus and other orthopoxviruses. J Med Chem. 2023;66(7):4468\u201390.","journal-title":"J Med Chem"},{"key":"2355_CR19","unstructured":"Organization WH. Vaccines and immunization for monkeypox: interim guidance, 24 August 2022. World Health Organization; 2022."},{"issue":"1","key":"2355_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00527-4","volume":"7","author":"MF Gruber","year":"2022","unstructured":"Gruber MF. Current status of monkeypox vaccines. npj Vaccines. 2022;7(1):1\u20133.","journal-title":"npj Vaccines"},{"key":"2355_CR21","unstructured":"Patel M, Surti M, Adnan M. Artificial intelligence (AI) in monkeypox infection prevention. J Biomol Struct Dynamics, 2022: p. 1\u20135."},{"issue":"3","key":"2355_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12519-022-00618-1","volume":"19","author":"Y-M Dou","year":"2023","unstructured":"Dou Y-M, Yuan H, Tian H-W. Monkeypox virus: past and present. World J Pediatr. 2023;19(3):224\u201330.","journal-title":"World J Pediatr"},{"issue":"1","key":"2355_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","volume":"29","author":"LM Zaeck","year":"2023","unstructured":"Zaeck LM, et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023;29(1):270\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"2355_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, et al. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discovery. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discovery"},{"key":"2355_CR25","doi-asserted-by":"crossref","unstructured":"Zhang R-R et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerging Microbes & Infections, 2023(just-accepted): p. 2192815.","DOI":"10.1080\/22221751.2023.2192815"},{"issue":"1","key":"2355_CR26","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1038\/s41467-022-32638-w","volume":"13","author":"A Khalil","year":"2022","unstructured":"Khalil A, et al. Call for a unified approach to Monkeypox infection in pregnancy: lessons from the COVID-19 pandemic. Nat Commun. 2022;13(1):5038.","journal-title":"Nat Commun"},{"issue":"1","key":"2355_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01625-0","volume":"20","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S, et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. J Nanobiotechnol. 2022;20(1):1\u201326.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2355_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12985-022-01935-7","volume":"19","author":"O Gholizadeh","year":"2022","unstructured":"Gholizadeh O, et al. Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. Virol J. 2022;19(1):206.","journal-title":"Virol J"},{"issue":"1","key":"2355_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01122-3","volume":"21","author":"K Nasiri","year":"2023","unstructured":"Nasiri K, et al. Spotlight on the impact of viral infections on hematopoietic stem cells (HSCs) with a focus on COVID-19 effects. Cell Communication Signal. 2023;21(1):1\u201315.","journal-title":"Cell Communication Signal"},{"issue":"7","key":"2355_CR30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/v14071553","volume":"14","author":"NA Mohamed","year":"2022","unstructured":"Mohamed NA, et al. Think like a virus: toward improving Nanovaccine Development against SARS-CoV-2. Viruses. 2022;14(7):1553.","journal-title":"Viruses"},{"issue":"1","key":"2355_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00710-4","volume":"7","author":"Y Huang","year":"2022","unstructured":"Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct Target Therapy. 2022;7(1):1\u201322.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"2355_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jpids\/piac120","volume":"12","author":"ST Shulman","year":"2023","unstructured":"Shulman ST. Monkeypox emergence and the eradication of smallpox: an historical review. J Pediatr Infect Dis Soc. 2023;12(2):73\u20135.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"12","key":"2355_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1086\/498155","volume":"41","author":"RA Weinstein","year":"2005","unstructured":"Weinstein RA, et al. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005;41(12):1765\u201371.","journal-title":"Clin Infect Dis"},{"issue":"33","key":"2355_CR34","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1016\/j.vaccine.2020.04.062","volume":"38","author":"K Simpson","year":"2020","unstructured":"Simpson K, et al. Human monkeypox\u2013after 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020;38(33):5077\u201381.","journal-title":"Vaccine"},{"issue":"11","key":"2355_CR35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/v12111257","volume":"12","author":"E Alakunle","year":"2020","unstructured":"Alakunle E, et al. Monkeypox Virus in Nigeria: infection Biology, Epidemiology, and evolution. Viruses. 2020;12(11):1257.","journal-title":"Viruses"},{"key":"2355_CR36","doi-asserted-by":"crossref","unstructured":"Lansiaux E et al. The Virology of Human Monkeypox Virus (hMPXV): A Brief Overview 2022.","DOI":"10.1016\/j.virusres.2022.198932"},{"key":"2355_CR37","doi-asserted-by":"crossref","unstructured":"Cheema AY et al. Monkeypox: a review of clinical features, diagnosis, and treatment. Cureus, 2022. 14(7).","DOI":"10.7759\/cureus.26756"},{"issue":"1","key":"2355_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0014-5793(01)03144-1","volume":"509","author":"SN Shchelkunov","year":"2001","unstructured":"Shchelkunov SN, et al. Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001;509(1):66\u201370.","journal-title":"FEBS Lett"},{"issue":"14","key":"2355_CR39","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.3390\/ijms23147866","volume":"23","author":"D Kmiec","year":"2022","unstructured":"Kmiec D, Kirchhoff F. Monkeypox: a new threat? Int J Mol Sci. 2022;23(14):7866.","journal-title":"Int J Mol Sci"},{"key":"2355_CR40","doi-asserted-by":"crossref","unstructured":"Lum F-M, et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nature Reviews Immunology; 2022.","DOI":"10.1038\/s41577-022-00775-4"},{"key":"2355_CR41","doi-asserted-by":"publisher","first-page":"1076251","DOI":"10.3389\/fcimb.2023.1076251","volume":"13","author":"S Rampogu","year":"2023","unstructured":"Rampogu S, et al. An overview on monkeypox virus: Pathogenesis, transmission, host interaction and therapeutics. Front Cell Infect Microbiol. 2023;13:1076251.","journal-title":"Front Cell Infect Microbiol"},{"key":"2355_CR42","doi-asserted-by":"publisher","first-page":"109108","DOI":"10.1016\/j.clim.2022.109108","volume":"243","author":"A Al-Musa","year":"2022","unstructured":"Al-Musa A, Chou J, LaBere B. The resurgence of a neglected orthopoxvirus: immunologic and clinical aspects of monkeypox virus infections over the past six decades. Clin Immunol. 2022;243:109108.","journal-title":"Clin Immunol"},{"issue":"12","key":"2355_CR43","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/labinvest.3780373","volume":"81","author":"GM Zaucha","year":"2001","unstructured":"Zaucha GM, et al. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 2001;81(12):1581\u2013600.","journal-title":"Lab Invest"},{"issue":"2","key":"2355_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/cit703","volume":"58","author":"AM McCollum","year":"2014","unstructured":"McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58(2):260\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2355_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tim.2011.12.001","volume":"20","author":"MG Reynolds","year":"2012","unstructured":"Reynolds MG, Damon IK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 2012;20(2):80\u20137.","journal-title":"Trends Microbiol"},{"issue":"1","key":"2355_CR46","first-page":"ltad020","volume":"3","author":"MM Christodoulidou","year":"2023","unstructured":"Christodoulidou MM, Mabbott NA. Efficacy Smallpox Vaccines against Mpox Infections Hum. 2023;3(1):ltad020.","journal-title":"Efficacy Smallpox Vaccines against Mpox Infections Hum"},{"issue":"1","key":"2355_CR47","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-023-01574-6","volume":"8","author":"E Li","year":"2023","unstructured":"Li E, et al. Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduct Target Therapy. 2023;8(1):350.","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"2355_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3390\/vaccines11101541","volume":"11","author":"G Matusali","year":"2023","unstructured":"Matusali G, et al. Evaluation of Cross-immunity to the Mpox Virus due to historic smallpox vaccination. Vaccines. 2023;11(10):1541.","journal-title":"Vaccines"},{"issue":"1","key":"2355_CR49","doi-asserted-by":"publisher","first-page":"ltad020","DOI":"10.1093\/immadv\/ltad020","volume":"3","author":"MM Christodoulidou","year":"2023","unstructured":"Christodoulidou MM, Mabbott NA. Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy Adv. 2023;3(1):ltad020.","journal-title":"Immunotherapy Adv"},{"issue":"4","key":"2355_CR50","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.idnow.2023.104714","volume":"53","author":"S Jamard","year":"2023","unstructured":"Jamard S, et al. Resurgence of symptomatic Mpox among vaccinated patients: first clues from a new-onset local cluster. Infect Dis Now. 2023;53(4):104714.","journal-title":"Infect Dis Now"},{"key":"2355_CR51","unstructured":"Zucker R et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med, 2023."},{"issue":"1","key":"2355_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/pathogens10010006","volume":"10","author":"CD Suraweera","year":"2020","unstructured":"Suraweera CD, Hinds MG, Kvansakul M. Poxviral strategies to overcome host cell apoptosis. Pathogens. 2020;10(1):6.","journal-title":"Pathogens"},{"issue":"20","key":"2355_CR53","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1128\/JVI.00304-15","volume":"89","author":"WD Arndt","year":"2015","unstructured":"Arndt WD, et al. Evasion of the innate immune type I interferon system by monkeypox virus. J Virol. 2015;89(20):10489\u201399.","journal-title":"J Virol"},{"issue":"4","key":"2355_CR54","doi-asserted-by":"publisher","first-page":"e35086","DOI":"10.1371\/journal.pone.0035086","volume":"7","author":"PN Hudson","year":"2012","unstructured":"Hudson PN, et al. Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS ONE. 2012;7(4):e35086.","journal-title":"PLoS ONE"},{"key":"2355_CR55","doi-asserted-by":"crossref","unstructured":"Ejaz H et al. Emergence and dissemination of monkeypox, an intimidating global public health problem. J Infect Public Health, 2022.","DOI":"10.1016\/j.jiph.2022.09.008"},{"key":"2355_CR56","doi-asserted-by":"crossref","unstructured":"Li H et al. The land-scape of immune response to monkeypox virus. EBioMedicine, 2023. 87.","DOI":"10.1016\/j.ebiom.2022.104424"},{"issue":"11","key":"2355_CR57","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/pathogens11111248","volume":"11","author":"JR Ulloque-Badaracco","year":"2022","unstructured":"Ulloque-Badaracco JR, et al. Acceptance towards Monkeypox Vaccination: a systematic review and Meta-analysis. Pathogens. 2022;11(11):1248.","journal-title":"Pathogens"},{"issue":"37","key":"2355_CR58","doi-asserted-by":"publisher","first-page":"16262","DOI":"10.1073\/pnas.1005769107","volume":"107","author":"AW Rimoin","year":"2010","unstructured":"Rimoin AW, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci. 2010;107(37):16262\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2355_CR59","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3201\/eid2704.203569","volume":"27","author":"P-Y Nguyen","year":"2021","unstructured":"Nguyen P-Y, et al. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017\u20132020. Emerg Infect Dis. 2021;27(4):1007.","journal-title":"Emerg Infect Dis"},{"key":"2355_CR60","doi-asserted-by":"crossref","unstructured":"Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. The Lancet Infectious Diseases; 2022.","DOI":"10.1016\/S1473-3099(22)00574-6"},{"key":"2355_CR61","unstructured":"Rizk JG et al. Prevention and treatment of monkeypox. Drugs, 2022: p. 1\u20137."},{"key":"2355_CR62","doi-asserted-by":"crossref","unstructured":"Kriss JL et al. Receipt of first and second doses of JYNNEOS vaccine for prevention of monkeypox\u2014United States, May 22\u2013October 10, 2022. Morbidity and Mortality Weekly Report, 2022. 71(43): p. 1374\u20131378.","DOI":"10.15585\/mmwr.mm7143e2"},{"key":"2355_CR63","doi-asserted-by":"crossref","unstructured":"Payne AB. Incidence of monkeypox among unvaccinated persons compared with persons receiving\u2009\u2265\u20091 JYNNEOS vaccine dose\u201432 US jurisdictions, July 31\u2013September 3, 2022. MMWR. Morbidity and Mortality Weekly Report, 2022. 71.","DOI":"10.15585\/mmwr.mm7140e3"},{"issue":"22","key":"2355_CR64","doi-asserted-by":"publisher","first-page":"p734","DOI":"10.15585\/mmwr.mm7122e1","volume":"71","author":"AK Rao","year":"2022","unstructured":"Rao AK, et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022. Morb Mortal Wkly Rep. 2022;71(22):p734.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"9","key":"2355_CR65","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/vaccines10091419","volume":"10","author":"A Abdelaal","year":"2022","unstructured":"Abdelaal A, et al. Preventing the next pandemic: is live vaccine efficacious against monkeypox, or is there a need for killed virus and mRNA vaccines? Vaccines. 2022;10(9):1419.","journal-title":"Vaccines"},{"issue":"5","key":"2355_CR66","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1002\/hsr2.798","volume":"5","author":"MR Islam","year":"2022","unstructured":"Islam MR, et al. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: a rapid review on comparative benefits and risks. Health Sci Rep. 2022;5(5):e798.","journal-title":"Health Sci Rep"},{"key":"2355_CR67","doi-asserted-by":"crossref","unstructured":"Vega-Rodriguez W, Ly H. GETTING AHEAD OF MONKEYPOX: learning from the COVID\u201019 pandemic experience to prevent the potentially new monkeypox pandemic. Journal of Medical Virology; 2022.","DOI":"10.1002\/jmv.28146"},{"issue":"11","key":"2355_CR68","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1073\/pnas.0406671102","volume":"102","author":"M Kidokoro","year":"2005","unstructured":"Kidokoro M, Tashiro M, Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci. 2005;102(11):4152\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2355_CR69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.7883\/yoken.JJID.2016.417","volume":"70","author":"I Iizuka","year":"2017","unstructured":"Iizuka I, et al. A single vaccination of nonhuman primates with highly attenuated smallpox vaccine, LC16m8, provides long-term protection against monkeypox. Jpn J Infect Dis. 2017;70(4):408\u201315.","journal-title":"Jpn J Infect Dis"},{"issue":"2","key":"2355_CR70","first-page":"1","volume":"64","author":"BW Petersen","year":"2015","unstructured":"Petersen BW, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. Morbidity Mortal Wkly Report: Recommendations Rep. 2015;64(2):1\u201326.","journal-title":"Morbidity Mortal Wkly Report: Recommendations Rep"},{"issue":"4","key":"2355_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1086\/505506","volume":"194","author":"MT Rock","year":"2006","unstructured":"Rock MT, et al. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J Infect Dis. 2006;194(4):435\u201343.","journal-title":"J Infect Dis"},{"key":"2355_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijid.2004.09.002","volume":"8","author":"TP Monath","year":"2004","unstructured":"Monath TP, et al. ACAM2000 clonal Vero cell culture Vaccinia virus (New York City Board of Health strain)\u2013a second-generation smallpox vaccine for biological defense. Int J Infect Dis. 2004;8:31\u201344.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"2355_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1586\/erv.09.55","volume":"8","author":"L Handley","year":"2009","unstructured":"Handley L, et al. The new ACAM2000\u2122 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev Vaccines. 2009;8(7):841\u201350.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"2355_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14760584.8.1.13","volume":"8","author":"JS Kennedy","year":"2009","unstructured":"Kennedy JS, Greenberg RN. IMVAMUNE\u00ae: modified Vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines. 2009;8(1):13\u201324.","journal-title":"Expert Rev Vaccines"},{"issue":"47\u201348","key":"2355_CR75","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","volume":"24","author":"J Kenner","year":"2006","unstructured":"Kenner J, et al. LC16m8: an attenuated smallpox vaccine. Vaccine. 2006;24(47\u201348):7009\u201322.","journal-title":"Vaccine"},{"key":"2355_CR76","doi-asserted-by":"crossref","unstructured":"Lozano JM, Muller S. Monkeypox: potential vaccine development strategies. Trends in Pharmacological Sciences; 2022.","DOI":"10.1016\/j.tips.2022.10.005"},{"issue":"10","key":"2355_CR77","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00705-021-05152-5","volume":"166","author":"J Hu","year":"2021","unstructured":"Hu J, et al. The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection. Arch Virol. 2021;166(10):2649\u201372.","journal-title":"Arch Virol"},{"issue":"1","key":"2355_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-022-02944-7","volume":"13","author":"S Yasamineh","year":"2022","unstructured":"Yasamineh S, et al. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19. Stem Cell Res Ther. 2022;13(1):1\u201323.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2355_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-022-01935-7","volume":"19","author":"O Gholizadeh","year":"2022","unstructured":"Gholizadeh O, et al. Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. Virol J. 2022;19(1):1\u201322.","journal-title":"Virol J"},{"issue":"1","key":"2355_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01376-x","volume":"21","author":"I Ahmad","year":"2023","unstructured":"Ahmad I, et al. An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor. Cell Communication Signal. 2023;21(1):1\u201316.","journal-title":"Cell Communication Signal"},{"key":"2355_CR81","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett KJ, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Controlled Release. 2021;335:237\u201346.","journal-title":"J Controlled Release"},{"key":"2355_CR82","doi-asserted-by":"crossref","unstructured":"Assefi M et al. A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system. J Drug Deliv Sci Technol, 2023: p. 104623.","DOI":"10.1016\/j.jddst.2023.104623"},{"issue":"27","key":"2355_CR83","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1016\/j.vaccine.2009.03.040","volume":"27","author":"JF Mann","year":"2009","unstructured":"Mann JF, et al. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1\/Th2 bias in the immune response and protection against infection. Vaccine. 2009;27(27):3643\u20139.","journal-title":"Vaccine"},{"key":"2355_CR84","doi-asserted-by":"publisher","first-page":"589959","DOI":"10.3389\/fchem.2020.589959","volume":"8","author":"ML Guevara","year":"2020","unstructured":"Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front Chem. 2020;8:589959.","journal-title":"Front Chem"},{"issue":"1","key":"2355_CR85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/pharmaceutics13010045","volume":"13","author":"IM Alfagih","year":"2020","unstructured":"Alfagih IM, et al. Nanoparticles as adjuvants and nanodelivery systems for mRNA-based vaccines. Pharmaceutics. 2020;13(1):45.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2355_CR86","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276.","journal-title":"J Nanobiotechnol"},{"key":"2355_CR87","unstructured":"Lee Y, et al. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Experimental & Molecular Medicine; 2023. pp. 1\u201312."},{"key":"2355_CR88","doi-asserted-by":"crossref","unstructured":"Freyn AW et al. A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge. bioRxiv, 2022.","DOI":"10.1101\/2022.12.17.520886"},{"issue":"716","key":"2355_CR89","doi-asserted-by":"publisher","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2023","unstructured":"Freyn AW, et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci Transl Med. 2023;15(716):eadg3540.","journal-title":"Sci Transl Med"},{"key":"2355_CR90","doi-asserted-by":"crossref","unstructured":"Sang Y et al. Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus. bioRxiv, 2022.","DOI":"10.1101\/2022.11.22.517500"},{"issue":"9","key":"2355_CR91","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","volume":"78","author":"J Hooper","year":"2004","unstructured":"Hooper J, et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol. 2004;78(9):4433\u201343.","journal-title":"J Virol"},{"issue":"11","key":"2355_CR92","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/v14112531","volume":"14","author":"J Fantini","year":"2022","unstructured":"Fantini J, Chahinian H, Yahi N. A vaccine strategy based on the identification of an annular ganglioside binding motif in Monkeypox virus protein E8L. Viruses. 2022;14(11):2531.","journal-title":"Viruses"},{"issue":"17","key":"2355_CR93","doi-asserted-by":"publisher","first-page":"1900101","DOI":"10.1002\/advs.201900101","volume":"6","author":"X Feng","year":"2019","unstructured":"Feng X, et al. Immunomodulatory nanosystems. Adv Sci. 2019;6(17):1900101.","journal-title":"Adv Sci"},{"issue":"3","key":"2355_CR94","doi-asserted-by":"publisher","first-page":"e01504","DOI":"10.1128\/JVI.01504-21","volume":"96","author":"EM Mucker","year":"2022","unstructured":"Mucker EM, et al. A nucleic acid-based orthopoxvirus vaccine targeting the Vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge. J Virol. 2022;96(3):e01504\u201321.","journal-title":"J Virol"},{"issue":"4","key":"2355_CR95","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00203-023-03480-5","volume":"205","author":"R Baghban","year":"2023","unstructured":"Baghban R, Ghasemian A, Mahmoodi S. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Arch Microbiol. 2023;205(4):150.","journal-title":"Arch Microbiol"},{"key":"2355_CR96","doi-asserted-by":"crossref","unstructured":"Banerji I, et al. RNA vaccines: the evolution, applications, and the challenges ahead, in Nucleic Acid Biology and its application in Human diseases. Springer; 2023. pp. 349\u201364.","DOI":"10.1007\/978-981-19-8520-1_10"},{"key":"2355_CR97","doi-asserted-by":"crossref","unstructured":"Reina J, Iglesias C. Vaccines against monkeypox Medicina Cl\u00ednica. English Edition); 2023.","DOI":"10.1016\/j.medcle.2023.01.005"},{"key":"2355_CR98","doi-asserted-by":"crossref","unstructured":"Roper RL et al. Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies. Vaccine, 2023.","DOI":"10.1016\/j.vaccine.2023.04.010"},{"key":"2355_CR99","doi-asserted-by":"crossref","unstructured":"Zeng C, et al. Formulation and delivery technologies for mRNA vaccines. Springer; 2020.","DOI":"10.1007\/82_2020_217"},{"issue":"7","key":"2355_CR100","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1021\/acsptsci.3c00047","volume":"6","author":"D Li","year":"2023","unstructured":"Li D, et al. Messenger RNA-Based therapeutics and vaccines: what\u2019s beyond COVID-19? ACS Pharmacol Translational Sci. 2023;6(7):943\u201369.","journal-title":"ACS Pharmacol Translational Sci"},{"key":"2355_CR101","doi-asserted-by":"crossref","unstructured":"Hussain A, et al. mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release; 2022.","DOI":"10.1016\/j.jconrel.2022.03.032"},{"issue":"3","key":"2355_CR102","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/vaccines11030507","volume":"11","author":"VP Chavda","year":"2023","unstructured":"Chavda VP, et al. mRNA-Based vaccine for COVID-19: they are New but not unknown! Vaccines. 2023;11(3):507.","journal-title":"Vaccines"},{"issue":"4","key":"2355_CR103","first-page":"390","volume":"9","author":"F Kowalzik","year":"2021","unstructured":"Kowalzik F, et al. mRNA-based Vaccines Vaccines. 2021;9(4):390.","journal-title":"mRNA-based Vaccines Vaccines"},{"issue":"4","key":"2355_CR104","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","volume":"136","author":"J Houseley","year":"2009","unstructured":"Houseley J, Tollervey D. The many pathways of RNA degradation. Cell. 2009;136(4):763\u201376.","journal-title":"Cell"},{"key":"2355_CR105","doi-asserted-by":"crossref","unstructured":"Bhattacharya M et al. Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach 2022. 64(5): p. 510\u2013525.","DOI":"10.1007\/s12033-021-00432-6"},{"key":"2355_CR106","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","volume":"89","author":"LA Brito","year":"2015","unstructured":"Brito LA, et al. Self-amplifying mRNA vaccines. Adv Genet. 2015;89:179\u2013233.","journal-title":"Adv Genet"},{"key":"2355_CR107","first-page":"31","volume":"440","author":"G Maruggi","year":"2022","unstructured":"Maruggi G, et al. Self-amplifying mRNA-Based Vaccine Technology and its Mode of Action. Curr Top Microbiol Immunol. 2022;440:31\u201370.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"2355_CR108","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","volume":"5","author":"NA Jackson","year":"2020","unstructured":"Jackson NA, et al. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines. 2020;5(1):11.","journal-title":"npj Vaccines"},{"issue":"1","key":"2355_CR109","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi N, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8(1):14630.","journal-title":"Nat Commun"},{"key":"2355_CR110","doi-asserted-by":"crossref","unstructured":"Granados-Riveron JT, Aquino-Jarquin G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Volume 142. Biomedicine & Pharmacotherapy; 2021. p. 111953.","DOI":"10.1016\/j.biopha.2021.111953"},{"key":"2355_CR111","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.virol.2015.01.019","volume":"479","author":"JL Hyde","year":"2015","unstructured":"Hyde JL, Diamond MS. Innate immune restriction and antagonism of viral RNA lacking 2\u05f3-O methylation. Virology. 2015;479:66\u201374.","journal-title":"Virology"},{"key":"2355_CR112","doi-asserted-by":"crossref","unstructured":"Palm A-KE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol, 2019: p. 1787.","DOI":"10.3389\/fimmu.2019.01787"},{"issue":"3","key":"2355_CR113","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","volume":"23","author":"A De Beuckelaer","year":"2017","unstructured":"De Beuckelaer A, Grooten J, De Koker S. Type I interferons modulate CD8\u2009+\u2009T cell immunity to mRNA vaccines. Trends Mol Med. 2017;23(3):216\u201326.","journal-title":"Trends Mol Med"},{"key":"2355_CR114","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3389\/fimmu.2019.01586","volume":"10","author":"M Brisse","year":"2019","unstructured":"Brisse M, Ly H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5. Front Immunol. 2019;10:1586.","journal-title":"Front Immunol"},{"issue":"3","key":"2355_CR115","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, et al. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med. 2020;26(3):311\u201323.","journal-title":"Trends Mol Med"},{"issue":"2","key":"2355_CR116","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines9020147","volume":"9","author":"E Bettini","year":"2021","unstructured":"Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines. 2021;9(2):147.","journal-title":"Vaccines"},{"issue":"1","key":"2355_CR117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40290-021-00417-5","volume":"36","author":"S Ramachandran","year":"2022","unstructured":"Ramachandran S, Satapathy SR, Dutta T. Delivery strategies for mRNA vaccines. Pharm Med. 2022;36(1):11\u201320.","journal-title":"Pharm Med"},{"key":"2355_CR118","doi-asserted-by":"crossref","unstructured":"Zeng C, et al. Formulation and delivery technologies for mRNA vaccines, in mRNA vaccines. Springer; 2020. pp. 71\u2013110.","DOI":"10.1007\/82_2020_217"},{"key":"2355_CR119","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00705-021-05152-5","volume":"166","author":"J Hu","year":"2021","unstructured":"Hu J, et al. The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection. Arch Virol. 2021;166:2649\u201372.","journal-title":"Arch Virol"},{"key":"2355_CR120","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586.","journal-title":"Int J Pharm"},{"issue":"1","key":"2355_CR121","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2012.202","volume":"21","author":"C Pollard","year":"2013","unstructured":"Pollard C, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"2355_CR122","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/vaccines9010065","volume":"9","author":"MD Buschmann","year":"2021","unstructured":"Buschmann MD, et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines. 2021;9(1):65.","journal-title":"Vaccines"},{"issue":"2","key":"2355_CR123","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.","journal-title":"Pharmaceutics"},{"issue":"3","key":"2355_CR124","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejps.2010.03.019","volume":"40","author":"CT de Ilarduya","year":"2010","unstructured":"de Ilarduya CT, Sun Y, D\u00fczg\u00fcne\u015f N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010;40(3):159\u201370.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2355_CR125","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7150\/thno.13515","volume":"6","author":"H Yu","year":"2016","unstructured":"Yu H, et al. Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer. Theranostics. 2016;6(1):14.","journal-title":"Theranostics"},{"key":"2355_CR126","doi-asserted-by":"publisher","first-page":"106893","DOI":"10.1016\/j.compbiomed.2023.106893","volume":"159","author":"Y Jin","year":"2023","unstructured":"Jin Y, et al. Proteomics-based vaccine targets annotation and design of subunit and mRNA-based vaccines for Monkeypox virus (MPXV) against the recent outbreak. Comput Biol Med. 2023;159:106893.","journal-title":"Comput Biol Med"},{"key":"2355_CR127","doi-asserted-by":"crossref","unstructured":"Aiman S et al. Immunoinformatic-guided novel mRNA vaccine designing to elicit immunogenic responses against the endemic Monkeypox virus. J Biomol Struct Dynamics, 2023: p. 1\u201315.","DOI":"10.1080\/07391102.2023.2233627"},{"issue":"1","key":"2355_CR128","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","volume":"8","author":"Y Sang","year":"2023","unstructured":"Sang Y, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against Vaccinia virus. Signal Transduct Target Therapy. 2023;8(1):172.","journal-title":"Signal Transduct Target Therapy"},{"key":"2355_CR129","doi-asserted-by":"crossref","unstructured":"Fang Z et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res, 2023: p. 1\u20134.","DOI":"10.1101\/2022.11.29.518427"},{"key":"2355_CR130","doi-asserted-by":"crossref","unstructured":"Hou F et al. Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge bioRxiv, 2022: p. 2022.11. 19.517190.","DOI":"10.1101\/2022.11.19.517190"},{"issue":"1","key":"2355_CR131","doi-asserted-by":"publisher","first-page":"2192815","DOI":"10.1080\/22221751.2023.2192815","volume":"12","author":"R-R Zhang","year":"2023","unstructured":"Zhang R-R, et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg Microbes Infections. 2023;12(1):2192815.","journal-title":"Emerg Microbes Infections"},{"issue":"5","key":"2355_CR132","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/v15051120","volume":"15","author":"N Rcheulishvili","year":"2023","unstructured":"Rcheulishvili N, et al. Development of a Multi-epitope Universal mRNA vaccine candidate for Monkeypox, Smallpox, and Vaccinia viruses: design and in Silico analyses. Viruses. 2023;15(5):1120.","journal-title":"Viruses"},{"key":"2355_CR133","doi-asserted-by":"crossref","unstructured":"Su C et al. A Quadrivalent mRNA immunization elicits potent immune responses against vaccinia and monkeypox viral antigens\u2013a step closer to a broad orthopoxvirus vaccine bioRxiv, 2023: p. 2023.04. 23.537951.","DOI":"10.1101\/2023.04.23.537951"},{"key":"2355_CR134","doi-asserted-by":"crossref","unstructured":"Zhang N et al. Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity. Sci China Life Sci, 2023: p. 1\u201313.","DOI":"10.1007\/s11427-023-2378-x"},{"key":"2355_CR135","doi-asserted-by":"crossref","unstructured":"Freyn AW et al. A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge BioRxiv, 2022: p. 2022.12. 17.520886.","DOI":"10.1101\/2022.12.17.520886"},{"key":"2355_CR136","doi-asserted-by":"publisher","first-page":"105668","DOI":"10.1016\/j.antiviral.2023.105668","volume":"216","author":"H Xia","year":"2023","unstructured":"Xia H, et al. Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice. Antiviral Res. 2023;216:105668.","journal-title":"Antiviral Res"},{"key":"2355_CR137","doi-asserted-by":"crossref","unstructured":"Sang Y et al. Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus bioRxiv, 2022: p. 2022.11. 22.517500.","DOI":"10.1101\/2022.11.22.517500"},{"key":"2355_CR138","doi-asserted-by":"crossref","unstructured":"Zeng J, et al. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Volume 12. Emerging Microbes & Infections; 2023. p. 2204151. 1.","DOI":"10.1080\/22221751.2023.2204151"},{"issue":"1","key":"2355_CR139","first-page":"1","volume":"12","author":"P Sookaromdee","year":"2023","unstructured":"Sookaromdee P, Wiwanitkit V. Protective immunity rate against monkeypox: expectation for present and future in case that there is no smallpox vaccine booster. Am J Clin Exp Immunol. 2023;12(1):1\u20135.","journal-title":"Am J Clin Exp Immunol"},{"issue":"5","key":"2355_CR140","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1473-3099(23)00185-8","volume":"23","author":"AR Raccagni","year":"2023","unstructured":"Raccagni AR, et al. Two individuals with potential monkeypox virus reinfection. Lancet Infect Dis. 2023;23(5):522\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2355_CR141","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/pharmaceutics14051101","volume":"14","author":"C Liu","year":"2022","unstructured":"Liu C, et al. Development of an LNP-encapsulated mRNA-RBD vaccine against SARS-CoV-2 and its variants. Pharmaceutics. 2022;14(5):1101.","journal-title":"Pharmaceutics"},{"key":"2355_CR142","doi-asserted-by":"crossref","unstructured":"Echaide M et al. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats 2023. 24(6).","DOI":"10.3390\/ijms24065944"},{"key":"2355_CR143","doi-asserted-by":"crossref","unstructured":"Aljabali AA et al. Monkeypox virus: an emerging epidemic. Microb Pathog, 2022: p. 105794.","DOI":"10.1016\/j.micpath.2022.105794"},{"key":"2355_CR144","doi-asserted-by":"crossref","unstructured":"Saadh MJ et al. Progress and prospects on vaccine development against Monkeypox Infection Microbial Pathogenesis, 2023: p. 106156.","DOI":"10.1016\/j.micpath.2023.106156"},{"issue":"10","key":"2355_CR145","doi-asserted-by":"publisher","first-page":"e29140","DOI":"10.1002\/jmv.29140","volume":"95","author":"X Yang","year":"2023","unstructured":"Yang X, et al. Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice. J Med Virol. 2023;95(10):e29140.","journal-title":"J Med Virol"},{"issue":"1","key":"2355_CR146","first-page":"5925","volume":"14","author":"F Hou","year":"2023","unstructured":"Hou F, Zhang Y, Liu X. mRNA Vaccines Encoding Fusion Proteins Monkeypox Virus Antigens Protect mice Vaccinia Virus Chall. 2023;14(1):5925.","journal-title":"mRNA Vaccines Encoding Fusion Proteins Monkeypox Virus Antigens Protect mice Vaccinia Virus Chall"},{"key":"2355_CR147","doi-asserted-by":"crossref","unstructured":"Chiu S et al. A mpox quadrivalent mRNA vaccine protects mice from a lethal vaccinia virus challenge 2023.","DOI":"10.21203\/rs.3.rs-3498501\/v1"},{"key":"2355_CR148","doi-asserted-by":"crossref","unstructured":"Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 vaccines. Vaccines (Basel), 2021. 9(9).","DOI":"10.3390\/vaccines9091033"},{"issue":"9","key":"2355_CR149","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/vaccines9091033","volume":"9","author":"MN Uddin","year":"2021","unstructured":"Uddin MN, Roni MA. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines. 2021;9(9):1033.","journal-title":"Vaccines"},{"issue":"12","key":"2355_CR150","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1377\/hlthaff.2023.00729","volume":"42","author":"AM Fox","year":"2023","unstructured":"Fox AM, Choi Y, Lin L. Substantial disparities in COVID-19 vaccine uptake and unmet immunization demand in low-and Middle-Income countries: Study examines COVID-19 vaccine uptake and unmet immunization demand in low-and middle-income countries. Health Aff. 2023;42(12):1697\u2013705.","journal-title":"Health Aff"}],"updated-by":[{"DOI":"10.1186\/s12951-024-02693-0","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"record-id":"54720"},{"DOI":"10.1186\/s12951-024-02693-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000}}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02355-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:04:03Z","timestamp":1720508643000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02355-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02355-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12951-024-02693-0","URL":"https:\/\/doi.org\/10.1186\/s12951-024-02693-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethical approval was not required as this umbrella review is a synthesis and analysis of existing studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare full consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}